NI201200051A - Nuevos maitansinoides y el uso de dichos maitansonoides para preparar conjugados con un anticuerpo. - Google Patents
Nuevos maitansinoides y el uso de dichos maitansonoides para preparar conjugados con un anticuerpo.Info
- Publication number
- NI201200051A NI201200051A NI201200051A NI201200051A NI201200051A NI 201200051 A NI201200051 A NI 201200051A NI 201200051 A NI201200051 A NI 201200051A NI 201200051 A NI201200051 A NI 201200051A NI 201200051 A NI201200051 A NI 201200051A
- Authority
- NI
- Nicaragua
- Prior art keywords
- maitansonoids
- maitansinoids
- antibody
- new
- prepare conjugates
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Abstract
La invención se refiere a un compuesto de fórmula (I), donde: ALK es un grupo alquileno (C1 - C6); X1 y X2 son cada uno independientemente uno de los grupos siguientes: -CH=CH-, -CO-, -CONR-, -NRCO-, -COO-, -OCO-, -OCONR-, -NRCOO-, -NRCONR'-, -NR-, -S(O)n (n=0, 1 ó 2) o -O-; R y R' son independientemente H o un grupo alquilo (C1 - C6); i es un número entero de 1 a 40, preferiblemente de 1 a 20, y más preferiblemente de 1 a 10; j es un número entero que corresponde a 1 cuando X2 es -CH=CH- y 2 cuando X2 no es -CH=CH-; Zb es un enlace sencillo, -O- o -NH- y Rb es H o o un grupo alquilo (C1- C6), cicloalquilo (C3 - C7), arilo, heteroarilo o heterocicloalquilo (C3 - C7); o Zb es un enlace sencillo y Rb es Hal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09305939 | 2009-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201200051A true NI201200051A (es) | 2012-08-09 |
Family
ID=41698152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201200051A NI201200051A (es) | 2009-10-02 | 2012-03-30 | Nuevos maitansinoides y el uso de dichos maitansonoides para preparar conjugados con un anticuerpo. |
Country Status (24)
Country | Link |
---|---|
US (1) | US20120276124A1 (es) |
EP (1) | EP2483279A1 (es) |
JP (1) | JP2013506653A (es) |
KR (1) | KR20120091166A (es) |
CN (1) | CN102741260A (es) |
AR (1) | AR078471A1 (es) |
AU (1) | AU2010302247A1 (es) |
BR (1) | BR112012007305A2 (es) |
CA (1) | CA2774916A1 (es) |
CL (1) | CL2012000820A1 (es) |
CR (1) | CR20120147A (es) |
EA (1) | EA201270473A1 (es) |
EC (1) | ECSP12011756A (es) |
IL (1) | IL218740A0 (es) |
MA (1) | MA33702B1 (es) |
MX (1) | MX2012003998A (es) |
NI (1) | NI201200051A (es) |
NZ (1) | NZ599045A (es) |
PE (1) | PE20121534A1 (es) |
TN (1) | TN2012000115A1 (es) |
TW (1) | TW201117814A (es) |
UY (1) | UY32913A (es) |
WO (1) | WO2011039721A1 (es) |
ZA (1) | ZA201202328B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2949469A1 (fr) * | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
AR078470A1 (es) * | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
UA116524C2 (uk) | 2011-03-29 | 2018-04-10 | Іммуноджен, Інк. | Спосіб одержання кон'югата антитіло-майтансиноїд |
RU2661083C2 (ru) | 2012-10-04 | 2018-07-11 | Иммуноджен, Инк. | Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент |
IN2015DN02349A (es) * | 2012-10-24 | 2015-08-28 | Polytherics Ltd | |
NO2789793T3 (es) * | 2012-10-24 | 2018-01-27 | ||
CN104650113A (zh) * | 2012-12-21 | 2015-05-27 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
US10570151B2 (en) | 2013-03-15 | 2020-02-25 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
US20160143914A1 (en) * | 2013-06-13 | 2016-05-26 | Emory University | Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof |
WO2015031396A1 (en) | 2013-08-26 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
CN103483357B (zh) * | 2013-10-12 | 2015-11-18 | 齐鲁制药有限公司 | 一种抗体-美登素偶联物的中间体新晶型及其制备方法 |
US9493413B2 (en) | 2013-11-27 | 2016-11-15 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
US9562059B2 (en) * | 2013-12-02 | 2017-02-07 | Hong Kong Baptist University | Anticancer maytansinoids with two fused macrocyclic rings |
GB201416960D0 (en) * | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
CA2966932A1 (en) | 2014-11-19 | 2016-05-26 | Immunogen, Inc. | Process for preparing cell-binding agent-cytotoxic agent conjugates |
CN106267225B (zh) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
CN106243127B (zh) | 2015-06-09 | 2021-01-26 | 凯惠科技发展(上海)有限公司 | 抗体药物偶联物、中间体、制备方法、药物组合物及应用 |
JP6638970B2 (ja) * | 2015-06-30 | 2020-02-05 | 株式会社 東北テクノアーチ | ヘテロ型単分散ポリエチレングリコール、ヘテロ型単分散ポリエチレングリコール製造用中間体の製造方法 |
BR112018014759B1 (pt) | 2016-01-25 | 2024-02-27 | Regeneron Pharmaceuticals, Inc | Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso |
EP3411077A1 (en) | 2016-02-05 | 2018-12-12 | ImmunoGen, Inc. | Efficient process for preparing cell-binding agent-cytotoxic agent conjugates |
US10195283B2 (en) * | 2016-03-18 | 2019-02-05 | R.P. Scherer Technologies, Llc | Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate |
CN107652219B (zh) | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
US6716821B2 (en) * | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
AU2003285878B2 (en) | 2002-11-07 | 2011-04-28 | Immunogen, Inc. | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
EP1626711A4 (en) * | 2003-05-09 | 2010-10-06 | Univ Pennsylvania | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
EP3851126A1 (en) | 2003-05-20 | 2021-07-21 | ImmunoGen, Inc. | Maytansinoid-cell-binding agent conjugates |
WO2005009369A2 (en) | 2003-07-21 | 2005-02-03 | Immunogen, Inc. | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
EP1669358A1 (en) | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
MX2007007590A (es) | 2004-12-22 | 2007-12-10 | Ambrx Inc | Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos. |
AU2006280146B2 (en) | 2005-08-09 | 2012-06-28 | Immunogen, Inc. | Method of acylating maytansinol with chiral amino acids |
ES2533992T3 (es) * | 2005-08-24 | 2015-04-16 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpo maitansinoide |
EP1832577A1 (en) | 2006-03-07 | 2007-09-12 | Sanofi-Aventis | Improved prodrugs of CC-1065 analogs |
EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
KR101528939B1 (ko) * | 2006-07-18 | 2015-06-15 | 사노피 | 암 치료를 위한 epha2에 대한 길항제 항체 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
EP2276506A4 (en) * | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
AR078470A1 (es) * | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
-
2010
- 2010-09-29 AR ARP100103531A patent/AR078471A1/es not_active Application Discontinuation
- 2010-09-29 TW TW099133090A patent/TW201117814A/zh unknown
- 2010-09-29 UY UY0001032913A patent/UY32913A/es not_active Application Discontinuation
- 2010-09-30 KR KR1020127011167A patent/KR20120091166A/ko not_active Application Discontinuation
- 2010-09-30 EA EA201270473A patent/EA201270473A1/ru unknown
- 2010-09-30 JP JP2012531540A patent/JP2013506653A/ja active Pending
- 2010-09-30 CN CN2010800548853A patent/CN102741260A/zh active Pending
- 2010-09-30 BR BR112012007305A patent/BR112012007305A2/pt not_active IP Right Cessation
- 2010-09-30 WO PCT/IB2010/054417 patent/WO2011039721A1/en active Application Filing
- 2010-09-30 EP EP10768578A patent/EP2483279A1/en not_active Withdrawn
- 2010-09-30 AU AU2010302247A patent/AU2010302247A1/en not_active Abandoned
- 2010-09-30 MX MX2012003998A patent/MX2012003998A/es unknown
- 2010-09-30 NZ NZ599045A patent/NZ599045A/xx not_active IP Right Cessation
- 2010-09-30 CA CA2774916A patent/CA2774916A1/en not_active Abandoned
- 2010-09-30 PE PE2012000428A patent/PE20121534A1/es not_active Application Discontinuation
-
2012
- 2012-03-14 TN TNP2012000115A patent/TN2012000115A1/en unknown
- 2012-03-19 IL IL218740A patent/IL218740A0/en unknown
- 2012-03-26 CR CR20120147A patent/CR20120147A/es unknown
- 2012-03-26 EC ECSP12011756 patent/ECSP12011756A/es unknown
- 2012-03-29 US US13/434,363 patent/US20120276124A1/en not_active Abandoned
- 2012-03-30 NI NI201200051A patent/NI201200051A/es unknown
- 2012-03-30 ZA ZA2012/02328A patent/ZA201202328B/en unknown
- 2012-04-02 CL CL2012000820A patent/CL2012000820A1/es unknown
- 2012-04-27 MA MA34818A patent/MA33702B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2483279A1 (en) | 2012-08-08 |
UY32913A (es) | 2011-04-29 |
BR112012007305A2 (pt) | 2016-12-06 |
US20120276124A1 (en) | 2012-11-01 |
WO2011039721A1 (en) | 2011-04-07 |
KR20120091166A (ko) | 2012-08-17 |
AR078471A1 (es) | 2011-11-09 |
TW201117814A (en) | 2011-06-01 |
TN2012000115A1 (en) | 2013-09-19 |
EA201270473A1 (ru) | 2013-02-28 |
NZ599045A (en) | 2013-09-27 |
CL2012000820A1 (es) | 2012-08-31 |
PE20121534A1 (es) | 2012-12-03 |
MA33702B1 (fr) | 2012-10-01 |
MX2012003998A (es) | 2012-04-20 |
CA2774916A1 (en) | 2011-04-07 |
CN102741260A (zh) | 2012-10-17 |
ECSP12011756A (es) | 2012-07-31 |
IL218740A0 (en) | 2012-06-28 |
ZA201202328B (en) | 2014-06-25 |
JP2013506653A (ja) | 2013-02-28 |
AU2010302247A1 (en) | 2012-04-26 |
CR20120147A (es) | 2012-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201200051A (es) | Nuevos maitansinoides y el uso de dichos maitansonoides para preparar conjugados con un anticuerpo. | |
AR106943A2 (es) | Compuestos de isoindolina y composiciones farmacéuticas de los mismos | |
WO2013156509A3 (en) | Sulfonium compounds, their preparation and use | |
AR083873A1 (es) | Derivados de acido amino-fenil-pentanoico sustituidos como inhibidores de nep | |
AR105340A2 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden | |
UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
ME00972B (me) | NOVI DERIVATI 6-TRIAZOLOPIRIDAZINSULFANIL BENZOTIAZOLA I BENZIMIDAZOLA, POSTUPAK ZA NJIHOVO DOBIJANJE l UPOTREBA KAO LJEKOVA l FARMACEUTSKIH KOMPOZICIJA l NOVA UPOTREBA KAO INHIBITORA MET-a | |
AR083676A1 (es) | Compuestos heterociclicos, útiles como inhibidores de quinasa y composiciones farmaceuticas que los contienen | |
UY31524A1 (es) | Nuevos compuestos 010 | |
AR057032A1 (es) | Tigeciclina y metodos de preparacion | |
ECSP10010722A (es) | Compuestos orgánicos | |
EA201300335A1 (ru) | Композиция, содержащая пирипиропеновый инсектицид и адъювант | |
WO2015004566A3 (en) | Liquid bisacylphosphine oxide photoinitiator | |
AR057324A1 (es) | Tigeciclina y metodos para preparar 9-aminominociclina | |
CO6450648A2 (es) | Compuesto ciclico que tiene grupo fenilo sustituido | |
TNSN08518A1 (en) | 18-methyl-19-nor-androst -4-en-17, 17 -spiroether (18-methyl-19-nor-20- spirox-4¬en-3-0ne) and pharmaceutical preparations containing the same | |
AR098270A1 (es) | Poliéster terminado en epoxi | |
AR088909A1 (es) | Compuestos de hidrocarburos aromaticos policiclicos que contienen un atomo de s o un grupo s(=o)₂ en su estructura basica | |
EA200801549A1 (ru) | Новые производные фенантридина в качестве антагонистов брадикинина | |
CY1112279T1 (el) | Εποξειδικη ενωση και μεθοδος για την παρασκευη της | |
AR104895A1 (es) | Conjugados fluorescentes | |
GB2508567A (en) | Light emitting composition and device | |
AR085770A1 (es) | Compuestos antibioticos derivados de homoeritromicina y composiciones farmaceuticas | |
EA201270277A1 (ru) | N-ацилированные октасахариды, активирующие рецепторы fgf, их получение и применение в терапии |